APUS

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $-49.6K ExitQ4 2025 $50k -- --
Jim SimonsRenaissance Technologies $-49.6K ExitQ4 2025 $50k -- --

News

prnewswire.comFor Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certificationprnewswire.comJun 8

businesswire.comApimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Programbusinesswire.comMay 5

globenewswire.comAPUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firmglobenewswire.comApr 26

businesswire.comApimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUSbusinesswire.comApr 16

Trade APUS

About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

CEO: Vinod Menon
IPO Date: May 9, 2025

Market Data

Open: $1.10
High: $1.36
Low: $1.10
Volume: 27.6K
52W High: $40.31
52W Low: $1.10

Valuation

Market Cap: $1.6M
Enterprise Value: $10M

Financials

Free Cash Flow: $-9.0M
Revenue: $0
Net Income: $-6.0M
Cash: $1.6M
Debt: $7.8M

Events

EarningsMay 26

actual -2.26